Fate Therapeutics (FATE) Competitors $1.40 -0.14 (-9.06%) As of 02:17 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends FATE vs. MAZE, VALN, STOK, CMPX, XERS, MGTX, HUMA, PGEN, AUTL, and TECXShould you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Maze Therapeutics (MAZE), Valneva (VALN), Stoke Therapeutics (STOK), Compass Therapeutics (CMPX), Xeris Biopharma (XERS), MeiraGTx (MGTX), Humacyte (HUMA), Precigen (PGEN), Autolus Therapeutics (AUTL), and Tectonic Therapeutic (TECX). These companies are all part of the "pharmaceutical products" industry. Fate Therapeutics vs. Maze Therapeutics Valneva Stoke Therapeutics Compass Therapeutics Xeris Biopharma MeiraGTx Humacyte Precigen Autolus Therapeutics Tectonic Therapeutic Fate Therapeutics (NASDAQ:FATE) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment. Do analysts prefer FATE or MAZE? Fate Therapeutics currently has a consensus price target of $6.75, suggesting a potential upside of 365.52%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Fate Therapeutics is more favorable than Maze Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30Maze Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to FATE or MAZE? In the previous week, Fate Therapeutics had 11 more articles in the media than Maze Therapeutics. MarketBeat recorded 12 mentions for Fate Therapeutics and 1 mentions for Maze Therapeutics. Fate Therapeutics' average media sentiment score of 0.71 beat Maze Therapeutics' score of -0.49 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of FATE or MAZE? 97.5% of Fate Therapeutics shares are held by institutional investors. 5.0% of Fate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community believe in FATE or MAZE? Fate Therapeutics received 480 more outperform votes than Maze Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformFate TherapeuticsOutperform Votes48068.09% Underperform Votes22531.91% Maze TherapeuticsN/AN/A Which has stronger valuation & earnings, FATE or MAZE? Maze Therapeutics has lower revenue, but higher earnings than Fate Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$63.53M2.60-$160.93M-$1.65-0.88Maze TherapeuticsN/AN/AN/AN/AN/A Is FATE or MAZE more profitable? Maze Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,325.43%. Maze Therapeutics' return on equity of 0.00% beat Fate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-1,325.43% -45.88% -33.95% Maze Therapeutics N/A N/A N/A SummaryFate Therapeutics beats Maze Therapeutics on 9 of the 12 factors compared between the two stocks. Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FATE vs. The Competition Export to ExcelMetricFate TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$165.14M$3.13B$5.81B$9.13BDividend YieldN/A1.57%4.78%3.85%P/E Ratio-0.8829.9025.9319.18Price / Sales2.60373.33463.3381.20Price / CashN/A183.5344.0437.47Price / Book0.393.647.714.77Net Income-$160.93M-$71.72M$3.18B$245.80M7 Day Performance2.11%0.03%-0.52%-0.80%1 Month Performance9.85%2.67%1.71%-0.44%1 Year Performance-78.77%-9.50%18.52%16.44% Fate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FATEFate Therapeutics4.2458 of 5 stars$1.41-9.1%$6.75+380.4%-78.1%$161.72M$63.53M-0.86550MAZEMaze TherapeuticsN/A$13.00-2.8%N/AN/A$569.14MN/A0.00121Gap DownVALNValneva2.2683 of 5 stars$6.93+7.2%$17.50+152.4%+9.6%$563.46M$165.52M-53.34700Analyst ForecastAnalyst RevisionGap DownSTOKStoke Therapeutics3.763 of 5 stars$10.28-9.5%$21.29+107.2%+62.5%$544.27M$8.78M-4.89100Analyst ForecastAnalyst RevisionNews CoverageCMPXCompass Therapeutics3.363 of 5 stars$3.90+11.5%$11.80+202.3%+67.3%$537.01MN/A-10.5520Analyst ForecastXERSXeris Biopharma3.7919 of 5 stars$3.56+0.1%$5.15+44.9%+25.6%$529.98M$163.91M-7.90290News CoverageMGTXMeiraGTx4.3414 of 5 stars$6.67-2.0%$23.50+252.2%+15.8%$521.50M$14.02M-5.51300Gap UpHUMAHumacyte3.1561 of 5 stars$4.14-0.4%$13.71+231.7%-22.5%$520.43M$1.57M-3.09150Short Interest ↓PGENPrecigen3.987 of 5 stars$1.78+4.4%$7.00+294.4%+38.7%$519.84M$6.22M-3.23190AUTLAutolus Therapeutics2.9777 of 5 stars$1.94-4.7%$10.40+437.5%-70.7%$514.88M$1.70M-1.60330Gap UpTECXTectonic Therapeutic2.7882 of 5 stars$34.80-4.5%$80.50+131.3%N/A$513.33MN/A-5.91120 Related Companies and Tools Related Companies Maze Therapeutics Alternatives Valneva Alternatives Stoke Therapeutics Alternatives Compass Therapeutics Alternatives Xeris Biopharma Alternatives MeiraGTx Alternatives Humacyte Alternatives Precigen Alternatives Autolus Therapeutics Alternatives Tectonic Therapeutic Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FATE) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FATE Stock Alerts